Hsu Min specialises in patents in the fields of chemistry, material science and pharmaceuticals. Her experience includes drafting and prosecuting patent applications in a wide range of technologies, including those relating to pharmaceuticals, catalytic processes, household products, electrochemistry, medical devices and polymers.
Hsu Min has a wealth of experience in European Oppositions and Appeals and regularly represents clients at Oral proceedings at the European Patent Office. She manages substantial patent portfolios and regularly provides clients with opinions on their freedom-to-operate in the light of third party rights. She works for a variety of clients including universities, start-ups and multi-national corporations.
Hsu Min has a First Class Masters’ Degree in Chemistry from Oxford University. She started in the patent profession in private practice in 1996, before joining the in-house patent department of a FTSE 100 multinational Oil & Gas company. She joined HGF as a Partner in 2011, having been a Partner at another major patent firm.
First Class Masters' Degree in Chemistry (University of Oxford)
January 14th 2021
September 21st 2020
March 3rd 2020
January 1st 1970
Hsu Min has given seminars about various aspects of intellectual property to students and academics at her local university. For example, she has presented at Fellowship Programmes for Entrepreneurs.
Managing Intellectual Property IP Stars 2021, comprising the highly recommended IP professionals, has now been published. HGF is delighted to have 14 European attorneys listed. IP STARS is the leading …Read article
Pharmaceutical and biotechnology patent applications also make top 10 most patented. Recent statistics published by the EPO show that a total of 14,295 European patent applications were filed in 2020 …Read article
The 2021 EPO Guidelines provide much needed guidance on how to protect antibodies in Europe. Biological drugs including therapeutic antibodies have become increasingly important to the pharmaceutical industry. The European …Read article
Opportunities for additional pharmaceutical product patent protection in Europe, based on the use of a drug to treat a patient exhibiting a biomarker indicative of drug response. Recent years have …Read article
Exploring the growth of patents for connected medical devices, and how best to protect them. The Internet of Things (IoT) is expected to change our lives by creating a connected …Read article
To waive, or not to waive, that is the question. The earliest identified date of a patient presenting with symptoms of a “novel coronavirus” in Wuhan, China is reported to …Read article
HGF in Europe and Knobbe Martens in the US are holding a joint webinar on 9th June. In this webinar we will explore considerations for implementing an effective strategy to …Event details
If you would like to discuss how HGF could help you, contact one of our IP specialists.